Coping with endothelial superoxide: Potential complementarity of arginine and high-dose folate

Medical Hypotheses

Volumn 63, Issue 4, 2004, Pages 709-718

  McCarty, Mark F ^a,b  

^a Pantox Laboratories   (United States)

^b NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ARGININE; ASCORBIC ACID; CYANOCOBALAMIN; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDIZING AGENT; POLICOSANOL; RALOXIFENE; SUPEROXIDE; TETRAHYDROBIOPTERIN;

AORTA; CYANOCOBALAMIN DEFICIENCY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME DEFICIENCY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; METABOLITE; METHYLATION; NONHUMAN; OXIDATIVE STRESS; PERNICIOUS ANEMIA; PRIORITY JOURNAL; REVIEW; SUPPLEMENTATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 8444221172     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2002.11.006     Document Type: Article

References (160)

1. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87:2000;840-844
2. Wolin M.S., Gupte S.A., Oeckler R.A. Superoxide in the vascular system. J. Vasc. Res. 39:2002;191-207
3. Meyer J.W., Holland J.A., Ziegler L.M., Chang M.M., Beebe G., Schmitt M.E. Identification of a functional leukocyte-type NADPH oxidase in human endothelial cells: a potential atherogenic source of reactive oxygen species. Endothelium. 7:1999;11-22
4. Zhang H., Schmeisser A., Garlichs C.D., Plotze K., Damme U., Mugge A., et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc. Res. 44:1999;215-222
5. Harrison D.G. Endothelial function and oxidant stress. Clin. Cardiol. 20:1997;II-7
6. Holland J.A., O'Donnell R.W., Chang M.M., Johnson D.K., Ziegler L.M. Endothelial cell oxidant production: effect of NADPH oxidase inhibitors. Endothelium. 7:2000;109-119
7. Cosentino F., Luscher T.F. Tetrahydrobiopterin and endothelial function. Eur. Heart. J. 19(Suppl G):1998;G3-G8
8. Katusic Z.S. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am. J. Physiol. Heart Circ. Physiol. 281:2001;H981-H986
9. Vasquez-Vivar J., Martasek P., Whitsett J., Joseph J., Kalyanaraman B. The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study. Biochem. J. 362:2002;733-739
10. Meneshian A., Bulkley G.B. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation. 9:1902;161-175
11. Rieger J.M., Shah A.R., Gidday J.M. Ischemia-reperfusion injury of retinal endothelium by cyclooxygenase- and xanthine oxidase-derived superoxide. Exp. Eye Res. 74:2002;493-501
12. Gewaltig M.T., Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc. Res. 55:2002;250-260
13. Sherman D.L., Keaney J.F.J., Biegelsen E.S., Duffy S.J., Coffrnan J.D., Vita J.A. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension. 35:2000;936-941
14. Virdis A., Ghiadoni L., Cardinal H., Favilla S., Duranti P., Birindelli R., et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J. Am. Coll. Cardiol. 38:2001;1106-1115
15. Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97:1996;22-28
16. Heitzer T., Just H., Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 94:1996;6-9
17. Ting H.H., Timimi F.K., Haley E.A., Roddy M.A., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation. 95:1997;2617-2622
18. Solzbach U., Hornig B., Jeserich M., Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation. 96:1997;1513-1519
19. Motoyama T., Kawano H., Kugiyama K., Hirashima O., Ohgushi M., Yoshimura M., et al. Endothelium-dependent vasodilation in the brachial artery is impaired in smokers: effect of vitamin C. Am. J. Physiol. 273:1997;H1644-H1650
20. Timimi F.K., Ting H.H., Haley E.A., Roddy M.A., Ganz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 31:1998;552-557
21. Taddei S., Virdis A., Ghiadoni L., Magagna A., Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 97:1998;2222-2229
22. Ito K., Akita H., Kanazawa K., Yamada S., Terashima M., Matsuda Y., et al. Comparison of effects of ascorbic acid on endothelium-dependent vasodilation in patients with chronic congestive heart failure secondary to idiopathic dilated cardiomyopathy versus patients with effort angina pectoris secondary to coronary artery disease. Am. J. Cardiol. 82:1998;762-767
23. Perticone F., Ceravolo R., Maio R., Cloro C., Candigliota M., Scozzafava A., et al. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis. 152:2000;511-518
24. Natali A., Sironi A.M., Toschi E., Camastra S., Sanna G., Perissinotto A., et al. Effect of vitamin C on forearm blood flow and glucose metabolism in essential hypertension. Arterioscler. Thromb. Vasc. Biol. 20:2000;2401-2406
25. Perticone F., Ceravolo R., Candigliota M., Venture G., lacopino S., Sinopoli F., et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes. 50:2001;159-165
26. Beckman J.A., Goldfine A.B., Gordon M.B., Creager M.A. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation. 103:2001;1618-1623
27. Schindler T.H., Magosaki N., Jeserich M., Olschewski M., Nitzsche E., Holubarsch C., et al. Effect of ascorbic acid on endothelial dysfunction of epicardial coronary arteries in chronic smokers assessed by cold pressor testing. Cardiology. 94:2000;239-246
28. Hamabe A., Takase B., Uehata A., Kurita A., Ohsuzu F., Tamai S. Impaired endothelium-dependent vasodilation in the brachial artery in variant angina pectoris and the effect of intravenous administration of vitamin C. Am. J. Cardiol. 87:2001;1154-1159
29. Williams M.J., Sutherland W.H., McCormick M.P., de Jong S.A., McDonald J.R., Walker R.J. Vitamin C improves endothelial dysfunction in renal allograft recipients. Nephrol. Dial. Transplant. 16:2001;1251-1255
30. Taddei S., Virdis A., Ghiadoni L., Salvetti G., Bernini G., Magagna A., et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension. 38:2001;274-279
31. Pleiner J., Schaller G., Mittermayer F., Bayerle-Eder M., Roden M., Wolzt M. FFA-induced endothelial dysfunction can be corrected by vitamin C. J. Clin. Endocrinol. Metab. 87:2002;2913-2917
32. Ogawa T., Kimoto M., Sasaoka K. Purification and properties of a new enzyme, NG,NG- dimethylarginine dimethylaminohydrolase, from rat kidney. J. Biol. Chem. 264:1989;10205-10209
33. Leiper J.M., Santa M.J., Chubb A., MacAllister R.J., Charles I.G., Whitley G.S., et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J. 343(Pt 1):1999;209-214
34. MacAllister R.J., Parry H., Kimoto M., Ogawa T., Russell R.J., Hodson H., et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol. 119:1996;1533-1540
35. Vallance P., Leone A., Calver A., Collier J., Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 20(Suppl 12):1992;S60-S62
36. Leiper J., Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 43:1999;542-548
37. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 99:1999;3092-3095
38. Stuhlinger M.C., Tsao P.S., Her J.H., Kimoto M., Balint R.F., Cooke J.P. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 104:2001;2569-2575
39. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 287:2002;1420-1426
40. McCarty MF. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine - an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Med. Hypotheses; 2002 (in press)
41. Cooke J.P. Does ADMA cause endothelial dysfunction? Arterioscler. Thromb. Vasc. Biol. 20:2000;2032-2037
42. Cooke J.P., Oka R.K. Atherogenesis and the arginine hypothesis. Curr. Atheroscler. Rep. 3:2001;252-259
43. Wascher T.C., Posch K., Wallner S., Hermetter A., Kostner G.M., Graier W.F. Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase? Biochem. Biophys. Res. Commun. 234:1997;35-38
44. Boger R.H., Bode-Boger S.M., Mugge A., Kienke S., Brandes R., Dwenger A., et al. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 317:1995;273-284
45. Heller R., Munscher-Paulig F., Grabner R., Till U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J. Biol. Chem. 274:1999;8254-8260
46. Huang A., Vita J.A., Venema R.C., Keaney J.F.J. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J. Biol. Chem. 275:2000;17399-17406
47. Stroes E., Kastelein J., Cosentino F., Erkelens W., Wever R., Koomans H., et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 99:1997;41-46
48. Maier W., Cosentino F., Lutolf R.B., Fleisch M., Seiler C., Hess O.M., et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J. Cardiovasc. Pharmacol. 35:2000;173-178
49. Heitzer T., Krohn K., Albers S., Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia. 43:2000;1435-1438
50. Setoguchi S., Mohri M., Shimokawa H., Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J. Am. Coll. Cardiol. 38:2001;493-498
51. Fukuda Y., Teragawa H., Matsuda K., Yamagata T., Matsuura H., Chayama K. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia. Heart. 87:2002;264-269
52. Setoguchi S., Hirooka Y., Eshima K., Shimokawa H., Takeshita A. Tetrahydrobiopterin improves impaired endothelium-dependent forearm vasodilation in patients with heart failure. J. Cardiovasc. Pharmacol. 39:2002;363-368
53. Higashi Y., Sasaki S., Nakagawa K., Fukuda Y., Matsuura H., Oshima T., et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am. J. Hypertens. 15:2002;326-332
54. Fukuda Y., Teragawa H., Matsuda K., Yamagata T., Matsuura H., Chayama K. Tetrahydrobiopterin improves coronary endothelial function, but does not prevent coronary spasm in patients with vasospastic angina. Circ. J. 66:2002;58-62
55. Ueda S., Matsuoka H., Miyazaki H., Usui M., Okuda S., Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J. Am. Coll. Cardiol. 35:2000;71-75
56. Heitzer T., Brockhoff C., Mayer B., Warnholtz A., Mollnau H., Henne S., et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ. Res. 86:2000;E36-E41
57. Milstien S., Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem. Biophys. Res. Commun. 263:1999;681-684
58. Kinoshita H., Milstien S., Wambi C., Katusic Z.S. Inhibition of tetrahydrobiopterin biosynthesis impairs endothelium-dependent relaxations in canine basilar artery. Am. J. Physiol. 273:1997;H718-H724
59. Shinozaki K., Nishio Y., Okamura T., Yoshida Y., Maegawa H., Kojima H., et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ. Res. 87:2000;566-573
60. Ishii M., Shimizu S., Nagai T., Shiota K., Kiuchi Y., Yamamoto T. Stimulation of tetrahydrobiopterin synthesis induced by insulin: possible involvement of phosphatidylinositol 3-kinase. Int. J. Biochem. Cell. Biol. 33:2001;65-73
61. Gorren A.C., List B.M., Schrammel A., Fitters E., Hemmens B., Wemer E.R., et al. Tetrahydrobiopterin-free neuronal nitric oxide synthase: evidence for two identical highly anticooperative pteridine binding sites. Biochemistry. 35:1996;16735-16745
62. Wever R.M., Luscher T.F., Cosentino F., Rabelink T.J. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation. 97:1998;108-112
63. Gokce N., Keaney J.F.J., Frei B., Holbrook M., Olesiak M., Zachariah B.J., et al. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 99:1999;3234-3240
64. Ellis G.R., Anderson R.A., Lang D., Blackman D.J., Morris R.H., Morris-Thurgood J., et al. Neutrophil superoxide anion-generating capacity, endothelial function and oxidative stress in chronic heart failure: effects of short- and long-term vitamin C therapy. J. Am. Coll. Cardiol. 36:2000;1474-1482
65. Levine G.N., Frei B., Koulouris S.N., Gerhard M.D., Keaney J.F.J., Vita J.A. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107-1113
66. Chambers J.C., McGregor A., Jean-Marie J., Obeid O.A., Kooner J.S. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 99:1999;1156-1160
67. Mays B.W., Freischlag J.A., Eginton M.T., Cambria R.A., Seabrook G.R., Towne J.B. Ascorbic acid prevents cigarette smoke injury to endothelium- dependent arterial relaxation. J. Surg. Res. 84:1999;35-39
68. Lekakis J.P., Anastasiou E.A., Papamichael C.M., Stamatelopoulos K.S., Dagre A.G., Alevizaki M.C., et al. Short-term oral ascorbic acid improves endothelium-dependent vasodilatation in women with a history of gestational diabetes mellitus. Diabetes Care. 23:2000;1432-1434
69. Williams M.J., Sutherland W.H., McCormick M.P., de Jong S.A., McDonald J.R., Walker R.J. Vitamin C improves endothelial dysfunction in renal allograft recipients. Nephrol. Dial. Transplant. 16:2001;1251-1255
70. Ling L., Zhao S.P., Gao M., Zhou Q.C., Li Y.L., Xia B. Vitamin C preserves endothelial function in patients with coronary heart disease after a high-fat meal. Clin. Cardiol. 25:2002;219-224
71. Pullin C.H., Bonham J.R., McDowell I.F., Lee P.J., Powers H.J., Wilson J.F., et al. Vitamin C therapy ameliorates vascular endothelial dysfunction in treated patients with homocystinuria. J. Inherit. Metab. Dis. 25:2002;107-118
72. Wilmink H.W., Stroes E.S., Erkelens W.D., Gerritsen W.B., Wever R., Banga J.D., et al. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 20:2000;185-188
73. Ek A., Strom K., Cotgreave I.A. The uptake of ascorbic acid into human umbilical vein endothelial cells and its effect on oxidant insult. Biochem. Pharmacol. 50:1995;1339-1346
74. Verhaar M.C., Stroes E., Rabelink T.J. Folates and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 22:2002;6-13
75. Stroes E.S., van Faassen E.E., Yo M., Martasek P., Boer P., Govers R., et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ. Res. 86:2000;1129-1134
76. Hyndman M.E., Verma S., Rosenfeld R.J., Anderson T.J., Parsons H.G. Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function. Am. J. Physiol. Heart Circ. Physiol. 282:2002;H2167-H2172
77. Verhaar M.C., Wever R.M., Kastelein J.J., van Dam T., Koomans H.A., Rabelink T.J. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 97:1998;237-241
78. De Vriese A.S., Van D.V., Blom H.J., Vanhoutte P.M., Verbeke M., Lameire N.H. The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia. 43:2000;1116-1125
79. Van Etten R.W., De Koning E.J., Verhaar M.C., Gaillard C.A., Rabelink T.J. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia. 45:2002;1004-1010
80. Doshi S.N., McDowell I.F., Moat S.J., Lang D., Newcombe R.G., Kredan M.B., et al. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler. Thromb. Vasc. Biol. 21:2001;1196-1202
81. Kaufman S. Some metabolic relationships between biopterin and folate: implications for the "methyl trap hypothesis" Neurochem. Res. 16:1991;1031-1036
82. Verhaar M.C., Wever R.M., Kastelein J.J., van Loon D., Milstien S., Koomans H.A., et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation. 100:1999;335-338
83. Doshi S.N., McDowell I.F., Moat S.J., Payne N., Durrant H.J., Lewis M.J., et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation. 105:2002;22-26
84. Gori T., Burstein J.M., Ahmed S., Miner S.E., Al-Hesayen A., Kelly S., et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation. 104:2001;1119-1123
85. Ubbink J.B. The role of vitamins in the pathogenesis and treatment of hyperhomocyst (e)inaemia. J. Inherit. Metab. Dis. 20:1997;316-325
86. Barchowsky A., Munro S.R., Morana S.J., Vincenti M.P., Treadwell M. Oxidant-sensitive and phosphorylation-dependent activation of NF-kappa B and AP-1 in endothelial cells. Am. J. Physiol. 269:1995;L829-L836
87. Pueyo M.E., Gonzalez W., Nicoletti A., Savoie F., Arnal J.F., Michel J.B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 20:2000;645-651
88. Ogata N., Yamamoto H., Kugiyama K., Yasue H., Miyamoto E. Involvement of protein kinase C in superoxide anion-induced activation of nuclear factor-kappa B in human endothelial cells. Cardiovasc. Res. 45:2000;513-521
89. Peng H.B., Libby P., Liao J.K. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J. Biol. Chem. 270:1995;14214-14219
90. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A.J., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96:1995;60-68
91. Laroux F.S., Lefer D.J., Kawachi S., Scalia R., Cockrell A.S., Gray L., et al. Role of nitric oxide in the regulation of acute and chronic inflammation. Antioxid. Redox Signal. 2:2000;391-396
92. Jiang J., Valen G., Tokuno S., Thoren P., Pernow J. Endothelial dysfunction in atherosclerotic mice: improved relaxation by combined supplementation with L-arginine-tetrahydrobiopterin and enhanced vasoconstriction by endothelin. Br. J. Pharmacol. 131:2000;1255-1261
93. Meyer J.W., Schmitt M.E. A central role for the endothelial NADPH oxidase in atherosclerosis. FEBS Lett. 472:2000;1-4
94. Heinloth A., Heermeier K., Raff U., Wanner C., Galle J. Stimulation of NADPH oxidase by oxidized low-density lipoprotein induces proliferation of human vascular endothelial cells. J. Am. Soc. Nephrol. 11:2000;1819-1825
95. Inoue N., Takeshita S., Gao D., Ishida T., Kawashima S., Akita H., et al. Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis. 155:2001;45-52
96. Rueckschloss U., Galle J., Holtz J., Zerkowski H.R., Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation. 104:2001;1767-1772
97. Meyer J.W., Holland J.A., Ziegler L.M., Chang M.M., Beebe G., Schmitt M.E. Identification of a functional leukocyte-type NADPH oxidase in human endothelial cells: a potential atherogenic source of reactive oxygen species. Endothelium. 7:1999;11-22
98. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C- dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 49:2000;1939-1945
99. Kashiwagi A., Shinozaki K., Nishio Y., Maegawa H., Maeno Y., Kanazawa A., et al. Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. Am. J. Physiol. 277:1999;E976-E983
100. Kashiwagi A., Shinozaki K., Nishio Y., Okamura T., Toda N., Kikkawa R. Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state. Diabetes Res. Clin. Pract. 45:1999;199-203
101. McCarty M.F. Endothelial membrane potential regulates production of both nitric oxide and superoxide-fundamental determinant of vascular health. Med. Hypotheses. 53:1999;277-289
102. Fedorova O.V., Talan M.I., Agalakova N.I., Lakatta E.G., Bagrov A.Y. Endogenous ligand of alpha (l) sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation. 105:2002;1122-1127
103. Lenda D.M., Sauls B.A., Boegehold M.A. Reactive oxygen species may contribute to reduced endothelium-dependent dilation in rats fed high salt. Am. J. Physiol. Heart Circ. Physiol. 279:2000;H7-H14
104. Howard A.B., Alexander R.W., Nerem R.M., Griendling K.K., Taylor W.R. Cyclic strain induces an oxidative stress in endothelial cells. Am. J. Physiol. 272:1997;C421-C427
105. Wung B.S., Cheng J.J., Shyue S.K., Wang D.L. NO modulates monocyte chemotactic protein-1 expression in endothelial cells under cyclic strain. Arterioscler. Thromb. Vasc. Biol. 21:2001;1941-1947
106. Wagner A.H., Kohler T., Ruckschloss U., Just I., Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 20:2000;61-69
107. Thakur N.K., Hayashi T., Sumi D., Kano H., Tsunekawa T., Iguchi A. HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide. Am. J. Physiol. Heart Circ. Physiol. 281:2001;H75-H83
108. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273:1998;24266-24271
109. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 95:1998;8880-8885
110. Wassmann S., Laufs U., Baumer A.T., Muller K., Ahlbory K., Linz W., et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 37:2001;1450-1457
111. Gouni-Berthold I., Berthold H.K. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am. Heart J. 143:2002;356-365
112. Menendez R., Amor A.M., Rodeiro I., Gonzalez R.M., Gonzalez P.C., Alfonso J.L., et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch. Med. Res. 32:2001;8-12
113. Wagner A.H., Schroeter M.R., Hecker M. 17beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells. FASEB J. 15:2001;2121-2130
114. Dantas A.P., Tostes R.C., Fortes Z.B., Costa S.G., Nigro D., Carvalho M.H. In vivo evidence for antioxidant potential of estrogen in microvessels of female spontaneously hypertensive rats. Hypertension. 39:2002;405-411
115. Wassmann S., Laufs U., Stamenkovic D., Linz W., Stasch J.P., Ahlbory K., et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation. 105:2002;2083-2091
116. Kappagoda C.T. Endothelial nitric oxide synthase and estrogen. Cardiovasc. Res. 47:2000;9-10
117. Andersen M.R., Stender S. Endothelial nitric oxide synthase activity in aorta of normocholesterolemic rabbits: regional variation and the effect of estrogen. Cardiovasc. Res. 47:2000;192-199
118. McNeill A.M., Zhang C., Stanczyk F.Z., Duckles S.P., Krause D.N. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke. 33:2002;1685-1691
119. Yang A.L., Tsai S.J., Jiang M.J., Jen C.J., Chen H. Chronic exercise increases both inducible and endothelial nitric oxide synthase gene expression in endothelial cells of rat aorta. J. Biomed. Sci. 9:2002;149-155
120. Nadaud S., Philippe M., Arnal J.F., Michel J.B., Soubrier F. Sustained increase in aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high blood flow. Circ. Res. 79:1996;857-863
121. Xiao Z., Zhang Z., Ranjan V., Diamond S.L. Shear stress induction of the endothelial nitric oxide synthase gene is calcium-dependent but not calcium-activated. J. Cell. Physiol. 171:1997;205-211
122. Silacci P., Formentin K., Bouzourene K., Daniel F., Brunner H.R., Hayoz D. Unidirectional and oscillatory shear stress differentially modulate NOS III gene expression. Nitric Oxide. 4:2000;47-56
123. Davis M.E., Cai H., Drummond G.R., Harrison D.G. Shear stress regulates endothelial nitric oxide synthase expression through c-Src by divergent signaling pathways. Circ. Res. 89:2001;1073-1080
124. Testa M., Ennezat P.V., Vikstrom K.L., Demopoulos L., Gentilucci M., Loperfido F., et al. Modulation of vascular endothelial gene expression by physical training in patients with chronic heart failure. Ital. Heart J. 1:2000;426-430
125. Griffin K.L., Woodman C.R., Price E.M., Laughlin M.H., Parker J.L. Endothelium-mediated relaxation of porcine collateral-dependent arterioles is improved by exercise training. Circulation. 104:2001;1393-1398
126. Gielen S., Hambrecht R. Effects of exercise training on vascular function and myocardial perfusion. Cardiol. Clin. 19:2001;357-368
127. Yoshizumi M., Perrella M.A., Burnett J.C.J., Lee M.E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res. 73:1993;205-209
128. Alonso J., Sanchez dM, Monton M., Casado S., Lopez-Farre A. Endothelial cytosolic proteins bind to the 3' untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. Mol. Cell. Biol. 17:1997;5719-5726
129. Gonzalez-Fernandez F., Jimenez A., Lopez-Blaya A., Velasco S., Arriero M.M., Celdran A., et al. Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. Atherosclerosis. 155:2001;61-70
130. Kuboki K., Jiang Z.Y., Takahara N., Ha S.W., Igarashi M., Yamauchi T., et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 101:2000;676-681
131. Aljada A., Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism. 49:2000;147-150
132. Ding Y., Vaziri N.D., Coulson R., Kamanna V.S., Roh D.D. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am. J. Physiol. Endocrinol. Metab. 279:2000;E11-E17
133. Luckhoff A., Busse R. Calcium influx into endothelial cells and formation of endothelium-derived relaxing factor is controlled by the membrane potential. Pflugers Arch. 416:1990;305-311
134. Michell B.J., Griffiths J.E., Mitchelhill K.I., Rodriguez-Crespo I., Tiganis T., Bozinovski S., et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 9:1999;845-848
135. Montagnani M., Chen H., Barr V.A., Quon M.J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser (1179. J. Biol. Chem. 276:2001;30392-30398
136. Lane P., Gross S.S. Disabling a C-terminal autoinhibitory control element in endothelial nitric-oxide synthase by phosphorylation provides a molecular explanation for activation of vascular NO synthesis by diverse physiological stimuli. J. Biol. Chem. 277:2002;19087-19094
137. Boo Y.C., Sorescu G., Boyd N., Shiojima I., Walsh K., Du J., et al. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser 1179 by Akt-independent mechanisms: role of protein kinase A. J. Biol. Chem. 277:2002;3388-3396
138. Michell B.J., Griffiths J.E., Mitchelhill K.I., Rodriguez-Crespo I., Tiganis T., Bozinovski S., et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 9:1999;845-848
139. Boger R.H., Skamira C., Bode-Boger S.M., Brabant G., Von Zur M., Frolich J.C. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J. Clin. Invest. 98:1996;2706-2713
140. Boger R.H. Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. J. Endocrinol. Invest. 22:1999;75-81
141. Fleming I., Hecker M., Busse R. Intracellular alkalinization induced by bradykinin sustains activation of the constitutive nitric oxide synthase in endothelial cells. Circ. Res. 74:1994;1220-1226
142. Ayajiki K., Kindermann M., Hecker M., Fleming I., Busse R. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells [see comments]. Circ. Res. 78:1996;750-758
143. Mizuno S., Demura Y., Ameshima S., Okamura S., Miyamori I., Ishizaki T. Alkalosis stimulates endothelial nitric oxide synthase in cultured human pulmonary arterial endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 283:2002;L113-L119
144. Celermajer D.S., Sorensen K.E., Spiegelhalter D.J., Georgakopoulos D., Robinson J., Deanfield J.E. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll. Cardiol. 24:1994;471-476
145. Lyons D., Roy S., Patel M., Benjamin N., Swift C.G. Impaired nitric oxide-mediated vasodilatation and total body nitric oxide production in healthy old age. Clin. Sci. (Lond.). 93:1997;519-525
146. Taddei S., Galetta F., Virdis A., Ghiadoni L., Salvetti G., Franzoni F., et al. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation. 101:2000;2896-2901
147. Singh N., Prasad S., Singer D.R., MacAllister R.J. Ageing is associated with impairment of nitric oxide and prostanoid dilator pathways in the human forearm. Clin. Sci. (Lond.). 102:2002;595-600
148. Csiszar A., Ungvari Z., Edwards J.G., Kaminski P., Wolin M.S., Koller A., et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ. Res. 90:2002;1159-1166
149. Matsushita H., Chang E., Glassford A.J., Cooke J.P., Chiu C.P., Tsao P.S. eNOS activity is reduced in senescent human endothelial cells: preservation by hTERT immortalization. Circ. Res. 89:2001;793-798
150. Minamino T., Miyauchi H., Yoshida T., Ishida Y., Yoshida H., Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 105:2002;1541-1544
151. van der Loo B., Labugger R., Skepper J.N., Bachschmid M., Kilo J., Powell
152. Taddei S., Virdis A., Ghiadoni L., Salvetti G., Bernini G., Magagna A., et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension. 38:2001;274-279
153. Csiszar A., Ungvari Z., Edwards J.G., Kaminski P., Wolin M.S., Koller A., et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ. Res. 90:2002;1159-1166
154. McCarty MF. Optimizing endothelial nitric oxide production may slow endothelial aging. Med. Hypotheses; 2002 (in press)
155. Chanarin I. Adverse effects of increased dietary folate. Relation to measures to reduce the incidence of neural tube defects. Clin. Invest. Med. 17:1994;244-252
156. Oakley G.P.J., Adams M.J., Dickinson C.M. More folic acid for everyone, now. J. Nutr. 126:1996;751S-755S
157. Dickinson C.J. Does folic acid harm people with vitamin B12 deficiency? QJM. 88:1995;357-364
158. Berlin H., Berlin R., Brante G. Oral treatment of pernicious anemia with high doses of vitamin B12 without intrinsic factor. Acta Med. Scand. 184:1968;247-258
159. Lederle F.A. Oral cobalamin for pernicious anemia. Medicine's best kept secret? JAMA. 265:1991;94-95
160. Hathcock J.N., Troendle G.J. Oral cobalamin for treatment of pernicious anemia? JAMA. 265:1991;96-97